5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy.
Keywords
Dihydropyrimidine Dehydrogenase Deficiency, Drug-Related Side Effects and Adverse Reactions, Genetic Testing, Fluorouracil, Pancytopenia
JancovaP, AnzenbacherP, AnzenbacherovaE. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(2):103-16. [https://doi.org/10.5507/bp.2010.017]. [PMID:20668491]
PeyradeF, CupissolD, GeoffroisL, et al. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. Oral Oncol. 2013;49(6):482-91. [https://doi.org/10.1016/j.oraloncology.2013.01.005]. [PMID:23415727]
MeyerhardtJA, MayerRJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476. [PMID:15689586]
FalvellaFS, CaporaleM, CheliS, et al. Undetected toxicity risk in pharmacogenetic testing for Dihydropyrimidine Dehydrogenase. Int J Mol Sci. 2015;16(4):8884-95. [https://doi.org/10.3390/ijms16048884]. [PMID:25906475]
MeulendijksD, CatsA, BeijnenJH, SchellensJH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?Cancer Treat Rev. 2016;50:23-34. [https://doi.org/10.1016/j.ctrv.2016.08.002]. [PMID:27589829]
van KuilenburgABP, HäuslerP, SchalhornA, et al. Evaluation of 5-Fluorouracil pharmacokinetics in cancer patients with a C.1905+1G>A Mutation in DPYD by means of a bayesian limited sampling strategy. Clin Pharmacokinet. 2012;51(3):163-74. [https://doi.org/10.1007/BF03257473]. [PMID:22339448]
Etienne-GrimaldiM-C, BoyerJ-C, BeroudC, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. Plos One. 2017;12;(5)1-19.
MeulendijksD, HenricksLM, SonkeGS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639-50. [https://doi.org/10.1016/S1470-2045(15)00286-7]. [PMID:26603945]
DeenenMJ, MeulendijksD, CatsA, et al. Upfront Genotyping of DPYD * 2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227-34. [https://doi.org/10.1200/JCO.2015.63.1325]. [PMID:26573078]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email